Approximately 70%-80% of all breast cancers are hormone receptor–positive (HR+), with tumor cells expressing either the estrogen receptor (ER), progesterone receptor (PR), or both. Testing for human epidermal growth receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is undertaken at diagnosis to guide treatment decisions. More than 80% of HR+ tumors are HER2-negative (HER2-) so that HR+/HER2- breast cancer is the most common subtype of invasive breast cancer. Adjuvant therapy for breast cancer aims to treat micrometastatic disease. A cornerstone of treatment for HR+/HER2- breast cancer is adjuvant endocrine therapy (eg, aromatase inhibitors and/or tamoxifen with or without ovarian suppression).
How familiar are you with adjuvant therapy for this breast cancer subtype? Test your knowledge with this quick quiz.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Elwyn C. Cabebe, Stefania Morganti. Fast Five Quiz: Adjuvant Therapy for HR+, HER2- Breast Cancer - Medscape - Jan 11, 2023.